Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma
OBJECTIVE: To investigate the short-term clinical efficacy and safety of the Janus kinase inhibitor tofacitinib in patients with Nagashima-type palmoplantar keratoderma (NPPK). METHODS: A retrospective analysis was performed on 7 NPPK patients with a homozygous SERPINB7 c.796C>T mutation, treated with oral tofacitinib citrate (adults: 5 mg twice daily; children: 5 mg once daily). Efficacy and adverse events were evaluated at weeks 0, 4, 8, and 12. RESULTS: The cohort included 5 female and 2 male patients, including 2 children. The mean age at disease onset was 15.3 years, with onset at ≤ 10 years in 5 patients. All had palmoplantar keratosis; 2 had Achilles tendon and 3 wrist involvement. All patients had ineffective prior retinoid therapy. No adverse events occurred during tofacitinib treatment. Hyperkeratosis improved markedly in 4 (57%), mildly in 1 (14%), and showed no response in 2 (29%) patients. The mean keratotic severity score decreased from 6.89 to 4.25 (approx. 40% reduction). CONCLUSIONS: Tofacitinib may be effective for NPPK, but larger randomized controlled trials are required to confirm long-term efficacy and safety.
Authors
- Fanzhang Meng (ORCID: https://orcid.org/0009-0008-3427-5666)
- 徐东昭
- Chen Li (ORCID: https://orcid.org/0000-0002-8527-1680)
- Zhimin Lin
- Yuan Chen (ORCID: https://orcid.org/0000-0003-1611-1023)
Institutions
- Beijing University of Chinese Medicine (CN)
- Capital Medical University (CN)
- Southern University of Science and Technology (CN)
- ShenZhen People’s Hospital (CN)
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (CN)
- Beijing Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- JDDG Journal der Deutschen Dermatologischen Gesellschaft
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1111/ddg.70543
- Primary Topic
- Genetic and rare skin diseases.
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China